Despite intensive discussion regarding the application of targeting FGFR3 using receptor kinase inhibitors or ligand-trapping antibodies in UC treatment [31,32,33], little is known about the efficacy of the FGFR3 genetic interference strategy in UTUC treatment. The gene discussed is FGFR3; the disease is renal pelvis/ureter urothelial carcinoma.